The cardioprotective benefit and anti cancer synergy will certainly get FDA attention with the newly developed formulation and will likely come but in due course.... the 505(b)2 pathway is no longer appealing due to the longer IP life of RC220. Breakthrough designation would be a more relevant possibility.
- Forums
- ASX - By Stock
- [INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene
The cardioprotective benefit and anti cancer synergy will...
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.83 |
Change
0.005(0.27%) |
Mkt cap ! $306.5M |
Open | High | Low | Value | Volume |
$1.83 | $1.86 | $1.80 | $103.0K | 56.03K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1328 | $1.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.83 | 2881 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1328 | 1.805 |
4 | 3471 | 1.800 |
2 | 2389 | 1.795 |
4 | 8009 | 1.790 |
1 | 4534 | 1.785 |
Price($) | Vol. | No. |
---|---|---|
1.830 | 2881 | 3 |
1.835 | 150 | 1 |
1.840 | 245 | 1 |
1.850 | 1400 | 1 |
1.860 | 2449 | 2 |
Last trade - 12.31pm 01/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online